



Company Presentation September 2020

A subsidiary of **evogene**
DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Canonic Ltd. ("Subsidiary" or "Company") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. Canonic is using forward-looking statements in this presentation when it discusses its near-term value drivers, including statements to the effect that it will reach commercialization, its estimated market size, its short-term milestones and commercial milestones. For these statements, Evogene and Subsidiary claim the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Subsidiary and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Subsidiary's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Subsidiary and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or Subsidiary, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or Subsidiary.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene or Subsidiary.



OUR VISION

Commercialize effective,
precise and stable medical
cannabis products for
optimized therapeutic impact

A close-up photograph of cannabis buds, showing green trichomes and yellowish-orange pistils. The word "INTRODUCTION" is overlaid in white, bold, sans-serif capital letters in the center-left of the image.

INTRODUCTION

Company Overview

Founded in 2019 as a
spinoff from Evogene Ltd
(EVGN)

We aim to develop &
commercialize
medical cannabis products

We aim to bring products all
the way to the market starting
from genetics to reach patients


Our products under development
are based on
stable high yield plants
with optimized therapeutic effects

AI –based computational
platform seeks to empower our
plant breeding pipeline

Commercialization is
expected in early 2022, up to
4 products in the following 3 years

Global Cannabis Market

Medical cannabis is >60% of the global market
(source: prohibition partners Nov 2019)



Market Challenges & The Opportunity

THE CHALLENGES



STABILITY

Substantial variations within varieties produce inconsistent products and therefore inconsistent results



YIELD

Legalization is driving steep declines in market prices, giving advantage to high yield products



SPECIFICITY

Specific medical indications require tailored active compound profiles. To date, breeding efforts in the market mainly pushed THC levels

THE OPPORTUNITY- PLANT GENETICS MAY HOLD THE SOLUTION TO THE INDUSTRY'S BIGGEST CHALLENGES


Canonic Technology Powered By Evogene's GeneRator AI

CUTTING EDGE AI DRIVEN COMPUTATIONAL GENOMIC POWER TO TACKLE INDUSTRY CHALLENGES



Cannabis Value Chain

FROM GENOMICS TO PRODUCT



Canonic in the Cannabis Value Chain


Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain



One Stop Shop

From Genomics to Medical Cannabis Products

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain



PRODUCTS

Product Families Under Development

MetaYield⁺

Stable enhancement of **total plant** compounds.

Focus on **agronomic** and **consumer** traits.



Increased compounds per plant
[e.g. Increased trichomes prevalence]



Increased compounds per area
[e.g. Dwarf & early flowering]

Precise⁺

Stable enhancement of **specific active** compounds.

Focus on **therapeutic** traits.



Medical indication focus
[e.g. Pain & Inflammation]



Compound profile focus
[e.g. CBG, CBC]

MetaYield+ : First Commercial Product

Canonic expects to commercialize its first varieties during 2022

PRODUCT NAME- NOA 1

High THC

High yield

Big inflorescence

Dense trichomes



Status:
product
development



**Relevant
market segment:**
T20/C5



**Expected
launch in Israel:**
early 2022



Target markets:
Israel (170M\$*) & EU



*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

MetaYield+ : Second Commercial Product

Canonic expects to commercialize its first varieties during 2022



PRODUCT NAME- NOA 2

High THC

High yield

Big inflorescence



Status:
product
development



**Relevant
market segment:**
T20/C5



**Expected
launch in Israel:**
early 2022



Target markets:
Israel (170M\$*) & EU

*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

Introduction to **Precise+** Product Family

Medical indication focus



Inflammation



Chronic pain

We generate pre-clinical data to guide our breeding program towards specific medical indications

Next Generation Products

Canonic is developing and validating its varieties in collaboration with leading research centers

Product 1

- 🔹 **Indication:** Inflammation
- 🔹 **Pre clinical study:** Hadassah medical center
- 🔹 **Status:** product development
- 🔹 **Expected launch in Israel:** 2023
- 🔹 **Target market size in Israel (2023):** 70M\$*



Product 2

- 🔹 **Indication:** Pain
- 🔹 **Pre clinical study:** Migal research center
- 🔹 **Status:** product development
- 🔹 **Expected launch in Israel:** 2023
- 🔹 **Target market size in Israel (2023):** 217 M\$*



*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel per medical indication

Technology



End-to-End Technologies

Developing in Israel's top cannabis R&D facilities



Large genetic & breeding collections



State of the art phenotypic tools



World leading computational capabilities



In-house Advanced-breeding



Fully equipped labs & tissue culture rooms




In house propagation




Unique Proprietary Database

Quality, Quantity and Variety of Information



Re-engineering traditional Cannabis breeding- Computational Technology

Unique database



Computational genomics



Proprietary Comparative Genomics

ATTTC**CG**ACAAGGATTAGT
AT**CG**CTTCACATAGGAAGT

Novel Genes & Markers
(IP protected)

THC / CBD / CBG /

Functional Cannabinoids patterns



High throughput plant breeding



Computed phenotyping



Genetic markers assisted selection



Pre-Clinical trials



MetaYield⁺
Precise⁺



Cutting-Edge Technology Addressing Market Challenges



Stability



Specificity



Yield



Reduced genetic variation



Diverse extracts for pre-clinical assays



Increased trichome density

Summary

Team



Dr. Arnon Heyman
CEO



Dr. Inbal Dangoor
Head of R&D



Guy Adler
Product manager & business
development



Dr. Michi Brog
Plant breeder



Aviv Filhaber
Agronomist



Barel Tal
Technician

Team

Board of directors



Ofer Haviv
Chairman of the board
Evogene CEO and President



Raanan Cohen
Business strategy
Former CEO Koor industries



Dorit Kreiner
Finance
Evogene CFO

Advisors




Dr. Yossi Tam
Cannabinoid clinical research
Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew university



Dr. Yariv Brotman
Plant metabolic pathways
Ben Gurion University & Max Planck
institute of Molecular Plant Physiology



Shai Leviatov
Plant breeding
Commercial varieties breeding for
more than 30 years in top leading
multinational seeds companies.



Adv. Itay Rosenferld
Business strategy
Cannabis entrepreneur and
former BOD member of
Intelicanna (TLV:INTL)



Nirit Elyovich
Marketing strategy
Senior marketing specialist with
over 20 years of B2C experience in
various markets

Short Term Milestones

2020




- ◆ Conduct pre-clinical studies to support the development of Canonic's medical cannabis products.
- ◆ Demonstrate yield improvement in cannabis lines under development.
- ◆ Engagement with commercial partners for cultivation and production.

2021



- ◆ Pre-commercial activity with first cannabis variety towards commercialization in 2022.
- ◆ Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.

Anticipated Commercial Milestones (5y)





Summary

Canonic aims to develop and **commercialize medical grade Cannabis** through a revolutionary genomic approach

Initial commercialization expected in 2022

Exclusive access to Evogene's CPB technology platform

Infrastructure in place – from seed to sale

Commercial partners in place for cultivation and production (IL & EU)

Leading **academic partnerships** for unique variety development



CANONIC
Cultivated by Science

THANK YOU